Top

Published in:

01-04-2006 | Adis Drug Profile

Insulin Glulisine

Authors: Dean M. Robinson, Keri Wellington

Published in: Drugs | Issue 6/2006

Abstract

▴ Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients.

▴ In large, well designed trials in patients with type 1 diabetes, insulin glulisine demonstrated a similar degree of glycaemic control, as measured by glycosylated haemoglobin (HbA_1c) levels, to RHI after 12 weeks and insulin lispro after 26 weeks.

▴ Pre-meal insulin glulisine was also more effective than RHI at controlling 2-hour post-prandial glucose excursions in patients with type 1 or 2 diabetes over a period of 12 weeks.

▴ In patients with type 2 diabetes, insulin glulisine induced significantly greater reductions in HbAic levels and 2-hour post-breakfast and post-dinner blood glucose levels than RHI over a period of 26 weeks.

▴ Insulin glulisine was generally well tolerated by patients with type 1 or 2 diabetes and had a similar safety profile to insulin lispro or RHI. Severe hypoglycaemia was experienced by similar proportions of insulin glulisine or comparator insulin (insulin lispro or RHI) recipients with type 1 or type 2 diabetes.

The use of trade names is for product identification purposes only and does not imply endorsement.

World Health Organisation. Diabetes action now [online]. Available from URL: http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf [Accessed 2004 Oct 13]

Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321(7258): 405–12PubMedCrossRef

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999 Aug 14; 354 (9178): 602]. Lancet 1998 Sep 12; 352 (9131); 837–53

American Diabetes Association. Insulin administration. Diabetes Care 2004 Jan; 27 Suppl. 1: S106–9CrossRef

Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001 Oct; 22(5): 706–17PubMedCrossRef

Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63(16): 1743–78PubMedCrossRef

Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004; 64(17): 1957–74PubMedCrossRef

Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997 Oct; 54(4): 597–614PubMedCrossRef

Aventis Pharmaceuticals Inc. Apidra™ insulin glulisine (rDNA origin) injection [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/0216291bl.pdf [Accessed 2006 Mar 20]

10.

Hennige AM, Strack V, Metzinger E, et al. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 2005 Jul 29; 48: 1891–7PubMedCrossRef

11.

Rakatzi I, Ramrath S, Ledwig D, et al. A novel insulin analog with unique properties: Lys(B3), Glu(B29) insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003 Sep; 52(9): 2227–38PubMedCrossRef

12.

Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced β-cell protective action. Biochem Biophys Res Commun 2003 Oct 24; 310(3): 852–9PubMedCrossRef

13.

Hennige AM, Lehmann R, Weigert C, et al. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 2005 Feb; 54(2): 361–6PubMedCrossRef

14.

Becker RH, Frick AD, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005 May; 113(5): 292–7PubMedCrossRef

15.

Becker RHA, Frick A, Wessels D. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P]. Diabetes 2003; 52 Suppl. 1: A110. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13–17; New Orleans (LA)

16.

Nosek L, Becker RHA, Frick AD, et al. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract no. 588-P]. Diabetes 2004; 53 Suppl. 2: A139–140. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

17.

Becker RHA, Frick AD, Kapitza CK, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]. Diabetes 2004; 53 Suppl. 2: A119. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

18.

Becker RH, Frick AD, Burger F, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005 Sep; 113(8): 435–43PubMedCrossRef

19.

Danne T, Becker RH, Heise T, et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005 Sep; 28(9): 2100–5PubMedCrossRef

20.

Frick A, Becker RHA, Wessels D, et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract no. 511-P]. Diabetes 2003; 52 Suppl. 1: A119. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13–17; New Orleans (LA)

21.

Gabry KE. Application number: 21–629 (Insulin glulisine). Medical Review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/21-629_Apidra.htm [Accessed 2004 Oct 15]

22.

Frick AD, Scholtz H, Burger F, et al. Absorption of insulin glulisine when mixed with NPH insulin [abstract no. 1329-P]. Diabetes 2004; 53 Suppl. 2: A321. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)CrossRef

23.

Jaros M, Martinek V, Piechatzek R, et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients [abstract no. 1330-P]. Diabetes 2004; 53 Suppl. 2: A321–322. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)CrossRef

24.

Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005 Nov; 37(11): 702–7PubMedCrossRef

25.

Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine [published erratum appears in Endocr Pract 2005; 11 (2): 145]. EndocrPract 2005 Jan–Feb; 11(1): 11–7

26.

Dailey G, Rosenstock J, Moses RWK, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004 Oct; 27(10): 2363–8PubMedCrossRef

27.

Pian LP, Sahlroot T. Application number: 21–629 (Insulin glulisine). Statistical review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/21-629_Apidra.htm [Accessed 2004 Oct 18]

28.

Hanaire-Broutin H, Schumicki DM, Hoogma RPL, et al. Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion [abstract no. 826]. Diabetologia 2004; 47 Suppl. 1: A298. Plus poster presented at the 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5–9; Munich

29.

Aventis Pharmaceuticals Inc. Aventis receives FDA approval of its rapid-acting insulin analogue Apidra® [online]. Available from URL: http://www.aventis.com [Accessed 2004 Nov 30]

30.

Aventis Pharmaceuticals Inc. Aventis announced European approval for Apidra® [online]. Available from URL: http://www.aventis.com [Accessed 2004 Dec 22]

Title: Insulin Glulisine
Authors: Dean M. Robinson
Keri Wellington
Publication date: 01-04-2006
Publisher: Springer International Publishing
Published in: Drugs / Issue 6/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666060-00011

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insulin Glulisine

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Bicalutamide 150mg

Gram-Positive Cocci Infections in Intensive Care

Sumatriptan Fast-Disintegrating/Rapid-Release Tablets

Rituximab

Gadofosveset

Lubiprostone